- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03854097
Effect of Intermittent Pressure in Patients With PAD
August 5, 2021 updated by: University of Dundee
Mechanistic Insights Into Changes in Blood Flow Following Application of Intermittent Negative Pressure
The study will evaluate the effect of intermittent negative pressure (INP) on peripheral arterial disease (PAD) patient vascular function and blood flow.
Patients will be given either -40mmHg INP or -10mmHg INP which will act as a placebo.
Healthy volunteers will be given -40mmHg INP to evaluate changes in vascular function and blood flow with INP in healthy physiology.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Atherosclerosis occurs when blood supply to the lower limbs is restricted upon accumulation of fat in the arteries.
Atheroslerosis in the lower limbs is termed peripheral arterial disease (PAD).
The initial symptom is pain in the lower limbs followed by ulceration and gangrene.
The literature has indicated that intermittent negative pressure (INP) can be used to reduce pain and facilitate wound healing.
INP is a non-invasive technique that aims to increase arterial and skin blood flow in lower limbs and foot.
This study aims to investigate the underlying mechanisms that are involved in changes in blood flow following application of INP.
The Flow-Ox 'boot' will be used to apply INP for periods ranging from 4-8 weeks, for an hour twice per day, to the lower limb to determine the effects of INP on vascular function and blood flow.
Specifically, vascular tests such as assessments of endothelial function, arterial stiffness, ankle-brachial pressure index (ABPI) and blood borne metabolic and inflammatory markers will be performed before and after INP application.
A pain chart will be employed before and after INP application to determine whether there is any change in perception of pain felt by individuals who suffer from pain associated with lower limb arterial disease.
Study Type
Interventional
Enrollment (Actual)
65
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Dundee, United Kingdom
- School of Medicine, University of Dundee, Ninewells Hospital & Medical School
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria
PAD Patients:
- Age ≥ 18 years
- Attending vascular outpatient clinics or admitted in ward with PAD.
- ABPI <0.9
Healthy Volunteers:
- Age ≥ 18 years
- No current or previous significant cardiovascular illness
- Able to give written informed consent
Exclusion criteria
PAD Patients:
- Unable to give written informed consent
- Patients with deep venous thrombosis
- Pregnant women
Healthy Volunteers:
- Positive medical history of: Vascular diseases such as PAD, stroke, IHD, hypertension... etc.
- Haematological conditions such as hypercoagulability, deep venous thrombosis... etc.,
- Alcohol excess
- Unable to give written informed consent
- Pregnant women
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Active PAD group
-40mmHg of Intermittent Negative Pressure (INP) for 4-8 weeks.
|
Application of -40mmHg negative pressure on the lower limb
|
Experimental: Placebo PAD group
-10mmHg of Intermittent Negative Pressure (INP) for 4-8 weeks.
|
Application of -10mmHg negative pressure on the lower limb
|
Experimental: Healthy Volunteers
-40 mmHg of Intermittent Negative Pressure (INP) for 5 days
|
Application of -40mmHg negative pressure on the lower limb
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in microvascular blood flow
Time Frame: Baseline, 1 day and 4-8 weeks
|
Microvascular blood flow measurement in foot using laser Dopper imaging.
|
Baseline, 1 day and 4-8 weeks
|
Change in microvascular endothelial function
Time Frame: Baseline, 1 day and 4-8 weeks
|
Peak blood perfusion response to acetylcholine (ACh) delivered by iontophoresis will be measured using a laser Doppler imager.
|
Baseline, 1 day and 4-8 weeks
|
Change in arterial stiffness
Time Frame: Baseline, 1 day and 4-8 weeks
|
Brachial pulse wave analysis (PWA) augmentation index (Ax) and carotid-femoral pulse wave velocity (m/s) (PWV) as an indication of arterial stiffness.
|
Baseline, 1 day and 4-8 weeks
|
Change in macrovascular endothelial function
Time Frame: Baseline, 1 day and 4-8 weeks
|
Brachial endothelial function measured as change in brachial blood vessel diameter (%) upon shear stress.
|
Baseline, 1 day and 4-8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in pain score
Time Frame: Baseline, 1 day and 4-8 weeks
|
Self-scoring of pain felt by patient on a visual analogue scale with 0 being no pain at all to 10 being the worst pain ever felt.
|
Baseline, 1 day and 4-8 weeks
|
Change in concentration of blood borne inflammatory and oxidative stress biomarkers
Time Frame: Baseline, 1 day and 4-8 weeks
|
Concentration of inflammatory and oxidative stress markers of endothelial activation/damage (including IL-1a, IL-6, IL-10, TNF-a, CRP, E-selectin and sICAM-1) measured in serum and plasma collected from patient blood samples.
|
Baseline, 1 day and 4-8 weeks
|
Change in Ankle-Brachial Pressure Index (ABPI)
Time Frame: Baseline, 1 day and 4-8 weeks
|
Brachial systolic pressure and ankle (dorsalis pedis) systolic pressure (mmHg) measured using Doppler probe. ABPI calculated as ankle systolic pressure divided by brachial systolic pressure. ABPI <0.9 = PAD, ABPI =>1.0 Normal. |
Baseline, 1 day and 4-8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jody McIntosh, PhD student
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 16, 2019
Primary Completion (Actual)
June 5, 2021
Study Completion (Actual)
June 5, 2021
Study Registration Dates
First Submitted
February 19, 2019
First Submitted That Met QC Criteria
February 22, 2019
First Posted (Actual)
February 26, 2019
Study Record Updates
Last Update Posted (Actual)
August 6, 2021
Last Update Submitted That Met QC Criteria
August 5, 2021
Last Verified
August 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1-014-18
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Arterial Disease
-
University of NebraskaNot yet recruitingPeripheral Arterial Disease | Peripheral Vascular Diseases | Peripheral Arterial Occlusive Disease | Peripheral Artery DiseaseUnited States
-
CID S.p.A.Meditrial Europe Ltd.Not yet recruitingPeripheral Arterial Occlusive Disease | Peripheral Artery DiseaseItaly
-
Marissa JarosinskiRecruitingPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Clopidogrel, Poor Metabolism of | Artery DiseaseUnited States
-
Stanford UniversityTerminatedPAD - Peripheral Arterial Disease | PVD- Peripheral Vascular DiseaseUnited States
-
Vascuros Medical Pte LtdNovella ClinicalUnknownPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery DiseaseSingapore, Belgium, Germany
-
Western Vascular Institute, IrelandRecruitingPeripheral Arterial Occlusive DiseaseIreland
-
Jena University HospitalAngioDroid s.r.l., Bologna (Italy)CompletedPeripheral Arterial Occlusive DiseaseGermany
-
Seoul National University HospitalAstellas Pharma Korea, Inc.CompletedPeripheral Arterial Occlusive DiseaseKorea, Republic of
-
Heidelberg UniversityTerminatedPeripheral Arterial Occlusive DiseaseGermany
-
Johann Wolfgang Goethe University HospitalSuspendedPeripheral Arterial Occlusive DiseaseGermany
Clinical Trials on Active Intermittent Negative Pressure (INP)
-
Otivio ASActive, not recruitingMultiple Sclerosis | Spasticity, Muscle | Pain, ChronicSweden
-
Oslo University HospitalOtivio ASCompletedIntermittent Claudication | Peripheral Artery Disease | Lower Extremity ClaudicationNorway
-
Oslo University HospitalOtivio ASCompletedWound Healing, Leg and Foot Ulcers, Macrocirculation, MicrocirculationNorway
-
Oslo University HospitalUniversity of Oslo; Otivio ASTerminatedPeripheral Arterial Disease | Renal Disease | Arterial Leg UlcersNorway
-
Brno University HospitalMasaryk UniversityRecruitingWeaning FailureCzechia
-
Milton S. Hershey Medical CenterRecruiting
-
ConvaTec Inc.Not yet recruitingSurgical Wound, Recent | Trauma-related Wound | Dehiscence Wound | Surgical Wound LeakUnited States
-
Mahidol UniversityEnrolling by invitationSurgical Site InfectionThailand
-
Milton S. Hershey Medical CenterNational Center for Advancing Translational Sciences (NCATS)Recruiting
-
Ahmed AljomahCompletedWound | Negative Pressure Wound TherapySaudi Arabia